1. Pink Sheet
  2. >>Market Access

Medicare Coverage For Alzheimer’s Treatments Should Have Flexibilities For Labeling Differences, Developers say

 
• By Cathy Kelly

Lilly and Genentech express concern that the Centers for Medicare and Medicaid Services will set Medicare coverage parameters for their Alzheimer’s drugs even before all the data is in.

Drug industry comments respond to Medicare national coverage analysis. • Source: Alamy

The Centers for Medicare and Medicare Services’ upcoming national coverage determination for amyloid-directed monoclonal antibody drugs for Alzheimer’s disease should be flexible enough to provide “appropriate” coverage for different therapies in the class based on individual labeling, Eli Lilly and Company and Genentech, Inc. urge in separate comments submitted to CMS 11 August.

A “class-based coverage determination may be premature,” Lilly said, adding: “We urge CMS to ensure that its coverage decision...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

BIO CEO On Industry And US FDA, Trump’s Vaccine Views And MFN Counter Proposals

 
• By Sarah Karlin-Smith

John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 
• By Neena Brizmohun

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

EU Pharma Reform: Council Wants Strengthened Member State Powers On Drug Supply

 
• By Eliza Slawther

The Council of the EU’s vision for the pharma reform package includes a stronger role for member states regarding the supply of medicines and the prevention of indication-stacking for orphan drugs.

ACIP ‘Pivot’ May Mean Variable US Coverage For New Vaccines, Higher Copays

 
• By Cathy Kelly

Clarity on payer responses to controversial vaccine recommendations from the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices may be coming.

More from Pink Sheet

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 
• By Neena Brizmohun

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

EU Pharma Reform: Council Wants Strengthened Member State Powers On Drug Supply

 
• By Eliza Slawther

The Council of the EU’s vision for the pharma reform package includes a stronger role for member states regarding the supply of medicines and the prevention of indication-stacking for orphan drugs.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.